What Is Spravato®?

For many people, depression is a condition that can be managed with traditional medications. But for others, standard treatments aren’t enough. This form of treatment-resistant depression (TRD) affects millions of adults, leaving them searching for new options.

Spravato® is the brand name for esketamine, a medication delivered as a nasal spray. In 2019, the U.S. Food and Drug Administration (FDA) approved Spravato for adults with treatment-resistant depression.

Many insurance companies now cover Spravato for eligible patients. This coverage can make treatment more affordable and accessible for adults struggling with treatment-resistant depression. If you are considering Spravato®, Renloft Health can help verify your insurance benefits and guide you through the approval process.

Unlike antidepressants you can pick up at the pharmacy and take at home, Spravato is available only in certified clinics. Patients self-administer the nasal spray while being monitored by a healthcare provider. This oversight is required because Spravato can cause temporary side effects such as dizziness, drowsiness, or changes in blood pressure.

Additional details on the medication may be found on Spravato.com